Glutamatergic Modulation of Disordered Alcohol Use
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Alcohol use disorders remain a significant public health problem. The pharmacological
facilitation of behavioral treatment represents a promising strategy for addressing
disordered drinking. Alcohol use disorders are recognized to be associated with various
vulnerabilities that complicate the course of treatment and that may be amenable to glutamate
modulators. The purpose of this randomized, double-blind, controlled trial is to test various
glutamate modulators in conjunction with motivational enhancement therapy (MET) for alcohol
use disorders.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
New York State Psychiatric Institute
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)